Salvo Health
Overview
Salvo Health is a New York-based virtual health clinic focused on providing comprehensive care for chronic gastrointestinal (GI) and metabolic liver conditions. It was founded in 2021 by tech veterans Jeff Glueck, Avi Dorfman, and Jason Finger. The company leverages a trademarked model called "Whole Self Science" to offer personalized and continuous treatment plans. As of 2025, Salvo Health has raised over $25.6 million in funding, involving investors like Threshold Ventures and City Light Capital.
Recent Developments
- March 2025: Salvo Health strategically partners with Pinnacle GI Partners, Michigan’s largest private gastroenterology practice, to expand "wraparound" care services in the Lansing and Detroit regions. This partnership aims to leverage telehealth technology to provide enhanced, continuous support for GI patients.
- February 2024: The company announces a $5 million Seed Prime round led by City Light Capital and Human Ventures to further expand their wraparound GI care model to additional health systems and private practices.
- July 2024: Salvo Health participates in the ACG gastroenterology meeting, during which they explore potential partnerships and unveil new initiatives targeted at improving GI healthcare delivery in the U.S.
- August 2023: Dr. Robert Hirten joins Salvo Health's Clinical Advisory Board to enhance predictive care models using data from consumer and medical devices.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2021 |
| Headquarters | New York City, NY, USA |
| Founders | Jeff Glueck, Avi Dorfman, Jason Finger |
| Revenue | Not publicly disclosed |
| Key Investors | Threshold Ventures, Torch Capital, Felicis Ventures |
| Industry | Health Technology |
| Number of Employees | 51-200 |
Early History
Founded in 2021, Salvo Health emerged as an innovative player in the healthcare industry, driven by the founders’ vision to enhance the management of chronic GI conditions. Jeff Glueck, alongside co-founders Avi Dorfman and Jason Finger, leveraged their extensive experience from companies like Foursquare and Seamless (now Grubhub) to address the gaps in conventional healthcare services, specifically for chronic gastrointestinal conditions. Initial seed funding of $10.5 million in 2022 enabled Salvo to develop and launch its virtual clinic platform.
Company Profile and Achievements
Salvo Health's business model integrates digital technology with human care to tackle chronic GI and metabolic liver conditions. Using their "Whole Self Science" approach, Salvo Health provides continuous, comprehensive care plans that extend beyond traditional episodic care. Significant milestones include:
- 2022: Launch of their virtual clinic, serving over 13 states which provided the groundwork for rapid expansion and development of app-based healthcare solutions.
- 2024: Salvo Health raises an additional $5 million to expand their technological and research capabilities.
- 2025: In collaboration with notable institutions like Pinnacle GI, Salvo Health further extends its reach, providing crucial wraparound services at a larger scale.
Current Operations and Market Position
As of 2025, Salvo Health stands as a notable leader in virtual GI and metabolic liver care. They have successfully implemented an interdisciplinary approach that includes behavioral health, dietetics, and remote patient monitoring. Salvo's proprietary technology allows for real-time adjustments to treatment plans, significantly improving patient outcomes. Their market position is strengthened by collaborations with industry leaders like Pinnacle GI and strategic partnerships with technology firms to enhance their care delivery models expediently.
Conclusion
Salvo Health has made significant strides in transforming the management of chronic conditions through its innovative virtual health clinic. It exemplifies a new direction for GI therapy, providing continuous, comprehensive care that integrates advanced digital tools with traditional clinical practices. As they expand their reach, Salvo Health is well-positioned to set new standards in the GI healthcare industry, promising further growth and innovation in the coming years.